VBIO Valion Bio (VBIO) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001787740
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · no price filed
What the filings say about VBIO
Activist stakes (13D), 180 days
1 filing
Largest: 9.9% of the class
Valion Bio insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Valion Bio, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 buys), the last on Jul 20, 2021.
- +0.0% median (+0.0% mean) 90-day return after 9 previous buys.
- The trade is 0.0% of the 4,711,651 shares held after it.
- No other insider bought within 30 days.
Insider activity: Insider LoConti Joseph E. bought about $200 of VBIO on Jul 29, 2021.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 buys), the last on Jul 19, 2021.
- +0.0% median (+0.0% mean) 90-day return after 8 previous buys.
- The trade is 0.3% of the 4,710,651 shares held after it.
- No other insider bought within 30 days.
Insider activity: Insider LoConti Joseph E. bought about $2.6K of VBIO on Jul 20, 2021.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Jul 9, 2021.
- +0.0% median (+0.0% mean) 90-day return after 7 previous buys.
- The trade is 0.4% of the 4,697,651 shares held after it.
- No other insider bought within 30 days.
Insider activity: Insider LoConti Joseph E. bought about $4.0K of VBIO on Jul 19, 2021, the largest insider purchase at the company on our record.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Jul 9, 2021.
- +0.0% median (+0.0% mean) 90-day return after 7 previous buys.
- The trade is 1.4% of the 4,677,651 shares held after it.
- No other insider bought within 30 days.
Insider activity: Insider LoConti Joseph E. bought about $12.7K of VBIO on Jul 19, 2021, the largest insider purchase at the company on our record.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Jul 9, 2021.
- +0.0% median (+0.0% mean) 90-day return after 7 previous buys.
- The trade is 0.9% of the 4,610,651 shares held after it.
- No other insider bought within 30 days.
Insider activity: Insider LoConti Joseph E. bought about $6.4K of VBIO on Jul 19, 2021, the largest insider purchase at the company on our record.14 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
-33.7% year over year
below 73% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
13.1% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 79% of Pharma & Biotech
The situation: each line is one rule over one dataset
3i, LP disclosed a 5%+ stake (9.9%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch VBIO
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-72.4%12M
13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns VBIO: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in VBIO
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
3i, LP
Activist 13D · 2026-08-03
9.9%
Tumim Stone Capital, LLC
Activist 13D · 2026-08-03
1.1%
3i Management LLC
Activist 13D · 2026-08-03
9.9%
Maier J. Tarlow
Activist 13D · 2026-08-03
9.9%
VBIO planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
VBIO financials
Revenue growth
-33.7%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$482.0K
four quarters, 2024-10-01 to 2025-09-30
Revenue, TTM VBIO
| FY Dec 2025 | $482.0K |
| FY Dec 2024 | $780.0K |
| FY Dec 2023 | $1.2M |
| FY Dec 2022 | $1.8M |
| FY Dec 2021 | $1.3M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | $146.0K |
| Jun 2025 | $86.0K |
| Mar 2025 | $70.0K |
| Dec 2024 | $180.0K |
| Sep 2024 | $126.0K |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM VBIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -701.0% |
| FY Dec 2022 | -548.4% |
| FY Dec 2021 | -675.7% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$14.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM VBIO
| FY Dec 2025 | -$7.0M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -$8.6M |
| FY Dec 2022 | -$8.9M |
| FY Dec 2021 | n/a |
| Jun 2026 | -$5.3M |
| Mar 2026 | -$5.0M |
| Dec 2025 | -$2.3M |
| Sep 2025 | -$2.0M |
| Jun 2025 | -$1.8M |
| Mar 2025 | -$889.0K |
| Dec 2024 | -$1.4M |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
1.74x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity VBIO
| FY Dec 2025 | 0.38x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 1.74x |
| Mar 2026 | 0.62x |
| Dec 2025 | 0.38x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-1.97x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt VBIO
| FY Dec 2025 | -1.08x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -1.97x |
| Mar 2026 | -1.61x |
| Dec 2025 | -1.08x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-472.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity VBIO
| FY Dec 2025 | -91.8% |
| FY Dec 2024 | -185.0% |
| FY Dec 2023 | -228.7% |
| FY Dec 2022 | -119.5% |
| FY Dec 2021 | -140.5% |
| Jun 2026 | -472.7% |
| Mar 2026 | -192.6% |
| Dec 2025 | -91.8% |
| Sep 2025 | -240.3% |
| Jun 2025 | -161.0% |
| Mar 2025 | -218.8% |
| Dec 2024 | -185.0% |
| Sep 2024 | -149.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-101.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets VBIO
| FY Dec 2025 | -51.6% |
| FY Dec 2024 | -142.0% |
| FY Dec 2023 | -149.5% |
| FY Dec 2022 | -96.6% |
| FY Dec 2021 | -56.5% |
| Jun 2026 | -101.4% |
| Mar 2026 | -64.7% |
| Dec 2025 | -51.6% |
| Sep 2025 | -156.0% |
| Jun 2025 | -136.5% |
| Mar 2025 | -160.7% |
| Dec 2024 | -142.0% |
| Sep 2024 | -123.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on invested capital VBIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employed VBIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | -142.3% |
| FY Dec 2023 | -212.7% |
| FY Dec 2022 | -113.4% |
| FY Dec 2021 | -40.8% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -138.5% |
| Jun 2025 | -121.4% |
| Mar 2025 | -164.1% |
| Dec 2024 | -142.3% |
| Sep 2024 | -145.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing VBIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$22.6M
market value at close 2026-10-27 on 2026-08-13 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value VBIO
| FY Dec 2025 | -$3.6M |
| FY Dec 2024 | $46.6M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $6.9M |
| Mar 2026 | $2.2M |
| Dec 2025 | -$3.6M |
| Sep 2025 | -$320.0K |
| Jun 2025 | $2.5M |
| Mar 2025 | $918.6K |
| Dec 2024 | $46.6M |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-84.6%
TTM free cash flow over market value at close 2026-10-27
FCF yield VBIO
| FY Dec 2025 | -274.8% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -19.2% |
| FY Dec 2022 | -0.1% |
| FY Dec 2021 | n/a |
| Jun 2026 | -881.6% |
| Mar 2026 | -437.9% |
| Dec 2025 | -274.8% |
| Sep 2025 | -194.6% |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -23.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing VBIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | n/a | $780.0K | $1.2M | $1.8M |
| Gross profit | n/a | $2.0K | $287.0K | $299.0K |
| Operating income | -$7.9M | -$4.5M | -$8.2M | -$10.1M |
| Net income | -$8.9M | -$5.7M | -$8.2M | -$10.1M |
| EPS (diluted) | n/a | -19.68 | -176.80 | -104.32 |
| Operating cash flow | -$7.0M | -$5.7M | -$8.5M | -$8.9M |
| Cash | $12.6M | $2.0M | $3.4M | $3.5M |
| Long-term debt | $6.5M | $0 | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
VBIO Stock Sonar score 4/7 axes
Find similar shapesCompareVBIO ranks highest on financial health (28th percentile) and growth (27th), and lowest on profitability (15th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
VBIO filings, in plain words
Read the full summary
1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 9.9% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
